Targeting ERBB2 mutations in solid tumors: biological and clinical implications

Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing results f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Cousin, Sophie, Khalifa, Emmanuel, Crombe, Amandine, Laizet, Yech’an, Lucchesi, Carlo, Toulmonde, Maud, Le Moulec, Sylvestre, Auzanneau, Céline, Soubeyran, Isabelle, Italiano, Antoine
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6019715/
https://ncbi.nlm.nih.gov/pubmed/29941010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0630-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados